DIAGNOSTIC DEALS

Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance

Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month

Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the … [Read more...]

INDUSTRY BUZZ

Industry Buzz: Qiagen and the Terrible, Horrible, No Good, Very Bad Day

Qiagen has been leaking oil for a while now. But after months of disappointing sales and dashed expectations, things came to a dramatic head over the less than 24 hour period between Oct. 7 and 8, … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Big picture-wise, health care industry mergers and acquisitions during the second quarter were up 7.3% from the first quarter and topped 250 deals for the eighth quarter in a row, according to … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The strategic deal making pot continues to boil, despite the relative inactivity of the established market leaders like Quest, LabCorp and Abbott. Here's a look at the trends and major deals from late … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Although not as frantic as the previous month, the pace of deal making remained rapid through the end of May to mid-June. Here's a quick overview of the trends and key deals. Mergers & … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The end of April through mid-May was another busy period for deal making. Here's a quick overview of activity and key deals. Mergers & Acquisitions and Asset Sales Thermo Fisher Scientific's … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The pace of diagnostic deal making picked up from the end of March through mid-April. Here's a quick overview of the activity and key deals made during the period. Mergers & Acquisitions and … [Read more...]

DIAGNOSTIC DEALS

Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

Spring has sprung with the announcement of a king-size deal: Danaher's $21.4 billion cash acquisition of GE Life Sciences, known as GE Biopharma, from General Electric Company (GE). Here's a quick … [Read more...]


(-00000g2)